UCB sales and marketing update

UCB launched Briviact brivaracetam in the U.S. to treat partial-onset seizures in epileptics ages 16 and older. The high affinity synaptic vesicle protein (SV2A) ligand is available in three formulations: tablet; oral solution; and injection. The wholesale acquisition cost (WAC) of a 10, 25, 50, 75 and 100 mg tablet is $15.16; the oral solution is $3.03 for 1 mL of 10 mg/mL solution; and the IV solution is $39 for a 5 mL container of 10 mg/mL solution. The recommended starting dose is 50 mg twice daily, and the dose may be adjusted to 25 or 100 mg twice daily. ...